Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease.

Key Findings:  We have provided the first evidence on the up-regulation of CB2 receptors in glial elements in postmortem tissues of PD patients, which has been confirmed in an inflammatory model of this disease. In addition, we have provided evidence on the benefits derived from their activation in relation with the activation of microglial cells, the infiltration of macrophages and also certain capability of these cells to generate proinflammatory factors.

Type of Study:  Animal Study

Study Result:  Positive

Cannabinoids Studied:  HU-x Synthetic Cannabinoids

Phytocannabinoid Source:  Not Applicable

Form of Administration:  Not Applicable

Receptors Studied:  CB2

Ligands Studied:  Dopamine

Study Location(s):  Spain

Year of Pub:  2016

Link to study